共 50 条
- [1] Cost effectiveness of zoledronic acid in the prevention of skeletal related events in renal cell carcinoma patients with bone metastases: An exploratory analysis for FranceJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Botteman, M.Kaura, S.Stephens, J.Foley, I.Chen, Y.
- [2] COST EFFECTIVENESS OF ZOLEDRONIC ACID IN THE PREVENTION OF SKELETAL RELATED EVENTS IN RENAL CELL CARCINOMA PATIENTS WITH BONE METASTASES: AN EXPLORATORY ANALYSIS FOR FRANCEEUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 157 - 157Botteman, M. F.Stephens, J.Foley, I.Kaura, S.
- [3] ZOLEDRONIC ACID IS COST EFFECTIVE FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES FROM RENAL CELL CARCINOMA: A FRENCH EXPLORATORY ANALYSISJOURNAL OF UROLOGY, 2009, 181 (04): : 500 - 500Botteman, Marc F.Stephens, Jennifer M.Foley, IsaacKaura, Satyin
- [4] COST EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PROSTATE CANCER PATIENTS WITH BONE METASTASES IN FRANCEANNALS OF ONCOLOGY, 2008, 19 : 201 - 201Meijboom, M.Botteman, M.Kaura, S.Durand-Zaleski, I.
- [5] COST EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PROSTATE CANCER PATIENTS WITH BONE METASTASES IN FRANCE AND GERMANYEUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 132 - 132Meijboom, M.Botteman, M. F.Kaura, S.
- [6] Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United KingdomEUROPEAN JOURNAL OF HEALTH ECONOMICS, 2011, 12 (06): : 575 - 588Botteman, M. F.Meijboom, M.Foley, I.Stephens, J. M.Chen, Y. M.Kaura, S.
- [7] Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United KingdomThe European Journal of Health Economics, 2011, 12 : 575 - 588M. F. BottemanM. MeijboomI. FoleyJ. M. StephensY. M. ChenS. Kaura
- [9] ZOLEDRONIC ACID IS COST EFFECTIVE FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES IN FRANCE AND GERMANYJOURNAL OF UROLOGY, 2009, 181 (04): : 295 - 295Meijboom, MarjanBotteman, Marc F.Kaura, Satyin
- [10] Zoledronic acid is cost saving and improves quality-adjusted survival in the prevention of skeletal related events in patients with bone metastases secondary to advanced renal cell carcinoma: a German perspectiveEJC SUPPLEMENTS, 2007, 5 (04): : 303 - 303Botteman, M.Foley, I.Marfatia, A.Chen, Y. M.